BeOne guideds2026 revenue to $6.2–$6.4B and GAAP operating income to $700–$800 million.
BeOne Medicines Ltd ADR reports fiscal Q4 2025 results with non-GAAP EPS $0.04 (+103% YoY) and revenue $1.5B (+33% YoY), misses EPS but beats revenue estimates
- Company reported fourth-quarter and full-year 2025 results, with full-year revenue growth of 33% year over year.
- BeOne Medicines returned to GAAP profitability in 2025 based on the reported full-year financial results.
- Company guided 2026 revenue to $6.2–$6.4B and GAAP operating income to $700–$800 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.